Sight Sciences (SGHT) Q3 2026 Earnings Call Transcript

Sight Sciences reported record Q3 2026 revenue of $24.9 million, up 25% year over year, and raised full-year revenue guidance to $92 million–$93 million from $88 million–$92 million while maintaining adjusted operating expense guidance of $92 million–$94 million. Interventional Dry Eye revenue rose 45% sequentially to $3.9 million, while Interventional Glaucoma revenue grew 7% year over year to $21 million; quarterly cash usage improved 74% to $2.4 million. Management cited the U.S. launch of OMNI Ultra, TearCare adoption and expanded payer coverage as growth drivers, while noting that broader dry-eye reimbursement decisions remain pending.

Analysis

SGHT’s key asymmetry is not the headline growth rate but whether reimbursed TearCare adoption converts into repeatable account-level utilization before broader payer access arrives. More accounts alone can mask shallow usage: the stronger signal is sustained growth in procedures per established account, alongside stable realized pricing and IDE gross margin. The FDA label may help payer discussions, but it is not equivalent to coverage; timing remains outside company control. Until fee schedules or coverage decisions are documented, treat management’s access outlook as an option, not the base case.

For the next 1–3 months, OMNI Ultra and the raised outlook can support sentiment, but the implied near-term IDE growth pace appears more measured than the sequential momentum. That gap may reflect prudent guidance—or early adoption variability. Over 6–18 months, payer expansion could improve the addressable market and commercial leverage; failure to broaden access leaves growth dependent on a limited reimbursed footprint. Established MIGS competitors, including Glaukos, remain a constraint on SGHT’s ability to translate category growth into share gains.

Cash-burn improvement lowers near-term financing concern, but one quarter does not establish a durable breakeven trajectory. Debt principal payments beginning in 2027 make execution on cash generation relevant; verify covenant terms, cash-flow conversion, and whether operating investment must rise to sustain growth. Without valuation and post-call price data, the earnings signal supports selective exposure rather than an unconditional chase.

Key Decisions for Investors

• Avoid chasing the initial earnings reaction without checking valuation and price response. Consider a starter long SGHT only if the stock holds post-call gains and subsequent results confirm improving utilization in existing IDE accounts; this is a growth-execution position, not yet a payer-access thesis.
• For the next quarterly update, track IDE ordering-account retention, SmartLids per mature account, realized pricing/gross margin, and verifiable new payer coverage. Faster account additions without deeper repeat utilization would weaken the quality of growth.
• Falsify the constructive thesis if IDE growth stalls absent new coverage, pricing or IDE gross margin retreats materially, IG growth turns negative after the OMNI Ultra rollout, or cash use rises enough to put the stated path to breakeven ahead of the 2027 principal-repayment period in doubt.
• No forced pair trade: without current valuation, borrow, and peer-performance data, the more useful alert is relative execution versus established MIGS competitors such as Glaukos, particularly on surgeon adoption and coverage.